Hida T, Velcheti V, Reckamp KL, et al. - Researchers undertook this phase 2, multicenter, open-label study, to test lenvatinib (a multityrosine kinase inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptors 1–4, RET, and other targets) for its safety and efficacy in patients with RET fusion-positive lung adenocarcinoma. They administered oral lenvatinib 24 mg/day in patients with RET-positive lung adenocarcinoma. The overall objective response rate was estimated to be 16% (95% CI: 4.5%–36.1%). The median progression-free survival (PFS) at data cutoff (February 3, 2016) was estimated to be 7.3 months (95% CI: 3.6–10.2) and the median overall survival was not reached. Hypertension (68%), nausea (60%), decreased appetite (52%), diarrhea (52%), and proteinuria (48%) were documented as the most commonly experienced treatment-emergent adverse events. Findings revealed the activity of lenvatinib in patients with RET fusion-positive lung adenocarcinomas. A relatively low response rate was reported but lenvatinib's activity in these patients was supported by the observed median PFS.